Clinical Trials

302 enrolled 1 FDA

Hematologic Neoplasms

NCT03399799 2026-06-05

MonumenTAL-1

279 enrolled 1 FDA

Hematologic Neoplasms

NCT03486873 2026-06-05

MK-3475-587

3,500 enrolled

Hematologic Neoplasms

NCT04634552 2026-06-05

MonumenTAL-1

Other hematologic neoplasmPlasma cell

510 enrolled 1 FDA

Multiple Myeloma, Hematologic Neoplasms

NCT04696809 2026-06-05

A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Completed

40 enrolled

Phase 3 Active not recruiting

Hematologic Neoplasms

NCT04971226 2026-06-05

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

405 enrolled 18 charts 1 FDA

MyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05424822 2026-06-05

A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

167 enrolled

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05453903 2026-06-05

A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

196 enrolled

Leukemia, Myeloid, Acute

NCT05712278 2026-06-05

A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia

Phase 1 Terminated

7 enrolled

Leukemia, Myeloid, Acute

NCT05748171 2026-06-05

A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

100 enrolled

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05963074 2026-06-05

TAILOR

320 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06299540 2026-06-05

QOLIBRI

Recruiting

180 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06618001 2026-06-05

A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

64 enrolled

Leukemia, Myeloid, Acute

NCT06651229 2026-06-05

A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

155 enrolled

Phase 1 Enrolling by invitation

Leukemia, Myeloid, Acute

NCT06788509 2026-06-05

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

120 enrolled

GenitourinaryLymphoidMyeloidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Prostatic Neoplasms, Castration-Resistant

NCT06852222 2026-06-05

cAMeLot-2

600 enrolled

Leukemia, Myeloid, Acute

NCT07295951 2026-06-05

A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia

10 enrolled

CNSGastrointestinalOther hematologic neoplasm

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07486713 2026-06-05

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Phase 4 Recruiting

16 enrolled

Glioma, Neoplasms, Leukemia, Myeloid, Acute, Cholangiocarcinoma

NCT07572006 2026-06-05

A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies

280 enrolled

Hematologic Neoplasms

NCT07602088 2026-06-05

REALITY-RO

Recruiting

60 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07629726 2026-06-05

A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms

Phase 1/2 Recruiting

72 enrolled

MyeloidOther hematologic neoplasmOther neoplasm

Hematologic Neoplasms

NCT02158858 2026-06-04

A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies

Phase 1/2 Completed

336 enrolled 61 charts

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Precancerous Conditions, Preleukemia, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT03960840 2026-06-04

Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

217 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04161885 2026-06-04

VIALE-T

Phase 3 Terminated

465 enrolled 20 charts

Neoplasms, Leukemia, Myeloid, Acute

NCT04502030 2026-06-04

Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

Phase 3 Completed

247 enrolled

Agammaglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT06943872 2026-06-04

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

630 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07255898 2026-06-04

A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies

Other hematologic neoplasmPlasma cell

33 enrolled

Multiple Myeloma, Hematologic Neoplasms

NCT05006716 2026-06-03

CaDAnCe-101

Phase 1/2 Recruiting

645 enrolled

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05091424 2026-06-03

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

137 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06973187 2026-06-03

A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

500 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07007312 2026-06-03

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

1,300 enrolled

Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT07139873 2026-06-03

A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)

250 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07277231 2026-06-03

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

500 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07586618 2026-06-03

ALT-101

24 enrolled

Phase 2/3 Not yet recruiting

Leukemia, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07623187 2026-06-03

EVICTION 3

450 enrolled

Leukemia, Myeloid, Acute

NCT07623616 2026-06-03

A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

6 enrolled

Leukemia, Myeloid, Acute

NCT03625037 2026-06-02

EPCORE™ NHL-1

666 enrolled 2 FDA

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT03802695 2026-06-02

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

LymphoidMyeloidOther hematologic neoplasm

300 enrolled

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04013685 2026-06-02

Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

LymphoidMyeloidOther hematologic neoplasm

155 enrolled

Blastic Plasmacytoid Dendritic Cell Neoplasm, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04542824 2026-06-02

EPCORE™ NHL-3

78 enrolled

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04623541 2026-06-02

EPCORE™ CLL-1

194 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05283720 2026-06-02

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

496 enrolled

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05557695 2026-06-02

EPIC

Recruiting

350 enrolled

Leukemia, B-Cell

NCT05753501 2026-06-02

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

135 enrolled

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT06539182 2026-06-02

DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)

155 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07306832 2026-06-02

A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

18 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT07384715 2026-06-02

First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)

78 enrolled

Leukemia, Myeloid, Acute

NCT05579132 2026-06-01

MK-1045-002

Phase 1/2 Recruiting

203 enrolled

Phase 3 Active not recruiting

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06073821 2026-06-01

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

652 enrolled